First quarter 2024 cash dividend of $0.165 per share
TEMPE, Ariz., March 11, 2024 /PRNewswire/ -- Benchmark Electronics, Inc. (NYSE: BHE) today announced that its Board of Directors declared a quarterly dividend of $0.165 per share, payable on April 12, 2024, to shareholders of record at the close of business on March 29, 2024.
About Benchmark Electronics, Inc. Benchmark provides comprehensive solutions across the entire product life cycle by leading through its innovative technology and engineering design services, leveraging its optimized global supply chain and delivering world-class manufacturing services in the following industries: commercial aerospace, defense, advanced computing, next generation telecommunications, complex industrials, medical, and semiconductor capital equipment. Benchmark's global operations include facilities in seven countries and its common shares trade on the New York Stock Exchange under the symbol BHE.
Perficient, Inc. ("Perficient" or "the Company"), a leading global digital consultancy transforming the world's largest enterprises and biggest brands, today announced that it has entered into a definitive agreement to be acquired by an affiliate of...
Perficient, Inc. ("Perficient"), the leading global digital consultancy transforming the world's largest enterprises and biggest brands, today reported its financial results for the quarter ended March 31, 2024.
Financial Highlights
For the...
A report from GDToday:
On the evening of May 3, 2024, the Guangzhou Opera House dazzled audiences with the performance of "Marco Polo," a captivating opera commissioned by the esteemed venue. In order to commemorate the 700th anniversary of the...
Garrett Smith, Founder and CEO of Community Capital Technology Inc. ("Community Capital"), will be attending the Milken Institute Global Conference ("MI Global") May 5-8, 2024 in Los Angeles. The event brings together global executives and...
Quarterhill Inc. ("Quarterhill" or the "Company") , a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS")...
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...
